Table III.
Association between expression of Tim-3 on CTLs and the clinicopathological parameters of breast infiltrating ductal carcinoma.
| Expression of Tim-3 on CTLs | |||||
|---|---|---|---|---|---|
| Variables | Patient no. (n=150) | Low (%) | High (%) | χ2 | P-value |
| Age, years | 3.160 | 0.075 | |||
| <45 | 48 | 18 (37.50) | 30 (62.50) | ||
| ≥45 | 102 | 24 (23.53) | 78 (76.47) | ||
| Tumor size | 10.177 | 0.017 | |||
| T1 | 51 | 15 (29.41) | 36 (70.59) | ||
| T2 | 36 | 6 (16.67) | 30 (83.33) | ||
| T3 | 60 | 18 (30.00) | 42 (70.00) | ||
| T4 | 3 | 3 (100.00) | 0 (0.00) | ||
| Lymph node status | 14.482 | 0.002 | |||
| N0 | 42 | 3 (7.14) | 39 (92.87) | ||
| N1 | 69 | 27 (39.13) | 42 (60.87) | ||
| N2 | 24 | 6 (25.00) | 18 (75.00) | ||
| N3 | 15 | 6 (40.00) | 9 (60.00) | ||
| TNM stage | 3.564 | 0.313 | |||
| I | 18 | 3 (16.67) | 15 (83.33) | ||
| II | 42 | 12 (28.57) | 30 (71.43) | ||
| III | 60 | 15 (25.00) | 45 (75.00) | ||
| IV | 30 | 12 (40.00) | 18 (60.00) | ||
| WHO grade | 9.939 | 0.007 | |||
| I | 15 | 9 (60.00) | 6 (40.00) | ||
| II | 99 | 27 (27.27) | 72 (72.72) | ||
| III | 36 | 6 (16.67) | 30 (83.33) | ||
| Ki-67 | 8.615 | 0.003 | |||
| <14% | 39 | 18 (46.15) | 21 (53.85) | ||
| ≥14% | 111 | 24 (21.62) | 87 (78.38) | ||
| Molecular classification | 23.636 | 0.000 | |||
| Luminal A | 24 | 9 (37.50) | 15 (62.50) | ||
| Luminal B | 60 | 27 (45.00) | 33 (55.00) | ||
| HER2-overexpressing | 36 | 6 (16.67) | 30 (83.33) | ||
| Basal-like | 30 | 0 (0.00) | 30 100.00) | ||
| Tim-3 expression on tumor | 0.946 | 0.331 | |||
| Low | 63 | 15 (23.80) | 48 (76.20) | ||
| High | 87 | 27 (31.03) | 60 (68.97) | ||
CTL, cytotoxic lymphocyte; TNM, tumor-node-metastasis; WHO, World Health Organization; HER2, human epidermal growth factor receptor 2; Tim-3, T-cell immunoglobulin and mucin domain-3.